New drug aims to shield autoimmune patients from Life-Threatening infections
NCT ID NCT07220915
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 6 times
Summary
This study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will track how many develop serious infections. The goal is to see if Panzyga can safely reduce infection risk in this vulnerable group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE CONDITIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos
ACTIVE_NOT_RECRUITINGKaunas, 50161, Lithuania
-
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
ACTIVE_NOT_RECRUITINGWarsaw, 02-637, Poland
-
P. Stradins Clinical University Hospital
ACTIVE_NOT_RECRUITINGRiga, 1002, Latvia
-
Perseverance Research Center, Phoenix Neurological Associates
RECRUITINGScottsdale, Arizona, 85253, United States
-
Riga East Clinical University Hospital
ACTIVE_NOT_RECRUITINGRiga, 1079, Latvia
-
UMHAT Sveti Georgi EAD
ACTIVE_NOT_RECRUITINGPlovdiv, 4002, Bulgaria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple shot under the skin replace an IV for a key antibiotic in the elderly?
- Experimental malaria vaccine aims to block parasite growth
- Rare disease drug shows promise in reducing infections
- New rapid test for infection and inflammation put to the test
- Fast new swab test could speed up vaginitis diagnosis
- Scientists crack the code of antibiotic-friendly superbug